Research programme: sodium channel blockers - RaQualia Pharma

Drug Profile

Research programme: sodium channel blockers - RaQualia Pharma

Alternative Names: RQ-00203066

Latest Information Update: 27 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer RaQualia Pharma
  • Class Amides
  • Mechanism of Action Nav1.3 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Inflammatory pain; Neuropathic pain

Most Recent Events

  • 27 Jul 2016 Early research and development is ongoing in Japan
  • 25 Jul 2016 Raqualia receives patent allowance for Sodium channel blockers in China
  • 25 Jul 2016 RaQualia has patent protection for Sodium channel blockers in Japan, USA, South Korea, Europe and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top